| Nasdaq: VRML
Vermillion, Inc. engages in the discovery, development and commercialization of novel high value diagnostic tests, which help physicians diagnose, treat and improve outcomes for patients. The company intends to develop novel diagnostics test in the fields of oncology, hematology, cardiology, and women's health with the initial focus on ovarian cancer. Its products include, OVA1, VASCLIR and OvaCalc. Vermillion was founded on December 9, 1993 and is headquartered in Austin, TX.